Fuzuloparib plus apatinib in BRCA-mutated breast cancer: balancing efficacy and accessibility in regional China.
0/5 보강
APA
Qiu Z, Jin N (2026). Fuzuloparib plus apatinib in BRCA-mutated breast cancer: balancing efficacy and accessibility in regional China.. The Lancet. Oncology, 27(3), e125. https://doi.org/10.1016/S1470-2045(25)00752-1
MLA
Qiu Z, et al.. "Fuzuloparib plus apatinib in BRCA-mutated breast cancer: balancing efficacy and accessibility in regional China.." The Lancet. Oncology, vol. 27, no. 3, 2026, pp. e125.
PMID
41785899 ↗
같은 제1저자의 인용 많은 논문 (5)
- Impact of breast reconstruction and different surgical approaches after neoadjuvant therapy on the long-term survival of breast cancer patients.
- The antitumor mechanisms of Huangqin Houpo decoction and its effect on chemotherapy-induced toxicity in colorectal cancer.
- PPP2R2A insufficiency enhances PD-L1 immune checkpoint blockade efficacy in lung cancer through cGAS-STING activation.
- Stearic acid-modified PSMA-targeting peptide-drug conjugate for long-acting prostate cancer therapy.
- NUP62 promotes breast cancer progression and inhibits ferroptosis by stabilizing NRF2 in a KEAP1-dependent way.